Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction

• Published in: Journal of thrombosis and thrombolysis Vol. 49; no. 2; pp. 235 - 244
• Main Authors: Owolabi, Ugochukwu Shola, Amraotkar, Alok Ravindra, Coulter, Amanda R., Singam, Narayana Sarma V., Aladili, Bahjat N., Singh, Ayesha, Trainor, Patrick James, Mitra, Riten, DeFilippis, Andrew Paul
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.02.2020; Springer Nature B.V
• Subjects: Adult; Aged; Atherosclerosis - blood; Atherosclerosis - diagnostic imaging; Biomarkers - blood; Cardiology; Cardiovascular disease; Cohort Studies; Coronary artery; Electrocardiography; Female; Follow-Up Studies; Gelatinase A; Gelatinase B; Health risk assessment; Heart attacks; Heart diseases; Hematology; Humans; Male; Matrix metalloproteinase; Matrix Metalloproteinase 2 - blood; Matrix Metalloproteinase 3 - blood; Matrix Metalloproteinase 9 - blood; Medicine; Medicine & Public Health; Metalloproteinase; Middle Aged; Myocardial infarction; Myocardial Infarction - blood; Myocardial Infarction - diagnostic imaging; Prospective Studies; Stromelysin 1; Thrombosis - blood; Thrombosis - diagnostic imaging; Extracellular matrix; Atherothrombosis; Acute myocardial infarction; Metalloproteinases
• ISSN: 0929-5305; 1573-742X; 1573-742X
• DOI: 10.1007/s11239-019-02004-7

Elevated measures of matrix metalloproteinases (MMPs) are associated with acute myocardial infarction (MI), but it is not known how long these changes persist post-MI or if these measures differ between atherothrombotic versus non-atherothrombotic MI. MMPs-2, 3, and 9 were measured in 80 subjects with acute MI (atherothrombotic and non-atherothrombotic MI) or stable coronary artery disease (CAD). Measurements were made at, the time of acute MI, and > 3-month following acute MI (quiescent phase). Outcome measures were compared between groups and between time of acute MI and quiescent post-MI follow-up using Wilcoxon’s and repeated measures analysis of variance. Forty-nine subjects met the criteria for acute MI with clearly defined atherothrombotic (n = 22) and non-atherothrombotic (n = 12) subsets. Fifteen subjects met criteria for stable CAD. MMP-3 was higher in acute MI versus stable CAD subjects at the time of acute MI: (453 vs. 217 pg/mL, p = 0.010) but not at quiescent phase follow-up (p > 0.05). MMP-9 was higher in acute MI versus stable CAD subjects at the time of acute MI: (412 vs. 168 pg/mL, p = 0.002) but not at the quiescent phase follow-up (p > 0.05). MMP-9 was higher at the time of acute MI versus quiescent phase follow-up in acute MI (412 vs. 213 pg/mL, p = 0.001) and atherothrombotic MI specifically (458 vs. 212 pg/mL, p = 0.001). No difference in MMP-2, 3, or 9 was observed between atherothrombotic versus non-atherothrombotic MI subgroups. MMPs-3 and 9 are significantly elevated in acute MI verses stable CAD subjects at time of acute MI but not different at quiescent phase follow-up. MMP-9 is elevated at the time of acute MI and specifically in acute atherothrombotic MI at time of MI versus quiescent phase follow-up.